

Fluconazole Resistance in *C. Tropicalis* by Broth Microdilution Method and to compare the relative gene expression of *erg11* gene in both Fluconazole Resistant and Sensitive *C Tropicalis*

SAHAR IMTIAZ¹, SIDRAH SALEEM², SONIA TAHIR³, MUHAMMAD IMRAN⁴, SHAH JAHAN⁵, SILA IMTIAZ⁶^{1,2}Department of Microbiology, University of Health Sciences, Lahore³Assistant Professor of Microbiology, Lahore Medical and Dental College, Lahore⁴Assistant Professor of Microbiology, University of Health Sciences, Lahore⁵Associate Professor of Immunology, University of Health Sciences, Lahore⁶M. Phil Microbiology, University of Health Sciences, LahoreCorrespondence to Dr. Sidrah Saleem, E-mail: sidrah.78@gmail.com, Cell: 0332 4796466

ABSTRACT

Aim: To evaluate fluconazole resistance among *C. tropicalis* by broth micro dilution method and relative expression of ergosterol (*ERG11*) gene in fluconazole resistant and sensitive *Candida tropicalis*.

Methods: The study design was comparative study conducted in Microbiology Department of UHS. A sum up of 66 confirmed isolates of *Candida tropicalis* were attained from Jinnah Hospital, Lahore. The fluconazole resistance of the isolates was determined by broth microdilution method and the relative gene expression of *ERG11* gene was analyzed by real time PCR, in Microbiology Department of UHS.

Results: The antibiotic susceptibility testing of *C. tropicalis* showed fifty one fluconazole sensitive, eight susceptible dose dependent and seven fluconazole resistant *C. tropicalis*. Relative gene expression of *ERG11* gene showed an increase expression about 2.0 fold in *C. tropicalis* resistant isolates than *C. tropicalis* susceptible isolates. Globally, *C. albicans* was the most frequently isolated species but now there is a decline in trend with increase figures for non-*albicans* *Candida* species. These non-*candida albicans* are now emerging as resistant species and cause serious ailments. This study showed seven fluconazole resistant *C. tropicalis* among sixty six isolates by broth microdilution method. Further on molecular testing by relative gene expression of *ERG11* gene it was noticed that these resistant isolates have 2.0 fold increased mRNA expression levels of this gene as compared to sensitive strains.

Conclusion: *C. tropicalis* was found to be resistant to fluconazole. Ergosterol expression was markedly raised in fluconazole resistant *C. tropicalis* in contrasted to drug sensitive *C. tropicalis*.

Keywords: *C. tropicalis*, fluconazole resistance antifungal susceptibility testing, non-*albicans* *Candida*, broth microdilution method, relative gene expression.

INTRODUCTION

Fungal pathogens have serious burden on the number of morbidity and mortality cases in clinically diagnosed high risk patients¹. However, to counteract the menace timely diagnosis and management of patients plays pivotal roles². The mainstream antifungal drugs taken into account are azoles, polyenes, echinocandins and pyrimidine analogs³. Fluconazole are the universally recommended antifungal medication to counter the fungal illnesses⁴. It is used as therapeutic medicine for superficial and systemic fungal infections being least harmful, low risk than other azoles, with immediate absorption, available in market in both oral and intravenous formulations⁵.

The azolic antifungal drugs acts by inactivating lanosterol 14 α -demethylase which further inhibit the biosynthesis of ergosterol. Ergosterol is an important compound for cell integrity and functions of cell membrane. The decrease in ergosterol biosynthesis leads to concomitant increase in the number of intermediate metabolites⁶. Furthermore, the changing trends of increasing number of fluconazole resistance among those *Candida* species which were once more susceptible such as *C. tropicalis* is worrisome⁷.

The azole resistance is rendered to its continuous use or some intrinsic factors such as change in expression level or mutations of *CDR1*, *CDR2*, *PDR5*^{8,9}, *ERG3*¹⁰, *MDR1*, *FLU11* and *ERG11*¹² genes.

To visualize the characteristics of biofilms formation and antifungal resistance, a study was conducted in Brazil on *C. tropicalis* and reported that sessile cells overexpressed *ERG11* and *MDR1* genes¹³. A study was carried out in China to detect the mechanisms of azole resistance. They take fifty two clinical isolates of *C. tropicalis* and quantified *CDR1*, *MDR1*, *CYT8* and

ERG11 genes and concluded that overexpression of *ERG11* gene was responsible for resistance¹⁴. Usually two main azole resistance mechanisms are mutations in *ERG11* gene which encodes a target enzyme 14- α -demethylase and multidrug efflux transporter genes i.e. *MDR/CDR* genes¹⁵.

Previously it has been reported that *ERG11* and *ERG3* genes encode proteins which are critically involved in ergosterol biosynthesis and point mutations of these two genes may alter the susceptibility to azole drugs¹⁶.

The objective of current study was to determine the fluconazole resistance among *C. tropicalis* by broth microdilution method and to compare the relative expression of *ERG11* gene in fluconazole resistant and sensitive *C. tropicalis*.

MATERIALS AND METHOD

After approval by the ethical review board, the study was executed in the Department of Microbiology and Resource Laboratory of University of Health Sciences, Lahore. A total of sixty six confirmed clinical isolates of *Candida tropicalis* were taken from Jinnah Hospital, Lahore. With facilitation of Broth microdilution procedure antifungal susceptibility was performed in micro titre plate as displayed in figure 1¹⁷. Inoculum compositions are exhibited in figure 2. Ten distinct testing compositions of fluconazole (640 μ g/ml, 320 μ g/ml, 160 μ g/ml, 80 μ g/ml, 40 μ g/ml, 20 μ g/ml, 10 μ g/ml, 5 μ g/ml, 2.5 μ g/ml and 1.25 μ g/ml) were assembled. In concordance with the results, *C. Tropicalis* was classified into three groups as sensitive (S) (\leq 8 μ g/ml), susceptible dose dependent (SDD) (16–32 μ g/ml) and resistant (R) (\geq 64 μ g/ml).

In facilitation with commercial kit, RNA was drawn out and the amount was evaluated by Nano drop. The drawn out RNA was transformed into cDNA by using cDNA synthesis kit. Thermal cycling conditions of polymerase chain reaction (PCR) for cDNA synthesis are exhibited in figure 3. To make sure that all RNA samples have been transformed to cDNA, conventional actin PCR was performed. Actin PCR thermal cycling conditions are shown in

Received on 24-11-2022

Accepted on 27-04-2023

figure 4. The synthesized cDNA (2µl) was also subjected to real time polymerase chain reaction (RT-PCR). Actin was used as an internal control in RT-PCR for relative gene expression of ERG11. The primers used for the expression analysis of ERG11 gene was ERG11-Forward primer:5'-TGCTGAAGAAGCTTATACCC-3' and ERG11-Reverse primer:5' CAAGGAATCAATCAATCTCTC-3' while the primers used for ACT (β -actin) were ACT Forward primer: 5'-TTTACGCTGGTTTCTCCTTGCC-3' and ACT Reverse primer: 5'-GCAGCTTCCAACCTAAATCGG-3'¹⁸.

SPSS 20 (Statistical Package for Social Sciences) was used for data evaluation; qualitative data was shown in frequencies and percentages as displayed in figure 5 and figure 6. Mean±SD was computed for quantitative variable e.g. MIC as shown in table 1. Relative gene expression of CtERG11 (*C. tropicalis*ERG11)gene of two types (sensitive and resistant *C. tropicalis*) were assessed by Mann Whitney U test. The median of sensitive group was 1.0 (IQR=1-1) and median of resistant group was 1.8 (IQR=2.7-1.5). There was statistically significant contrast between two groups and the p value was < 0.001.

RESULTS

The antifungal susceptibility testing, performed in microtitre plate by broth microdilution method revealed that out of sixtysix clinically isolated samples of *C. tropicalis* to fluconazole disclosed that 51 (77.3%) *C. tropicalis* were fluconazole receptive, 8 (12.1%) were dose related responsive and 7 (10.6%) were fluconazole resistant as shown in figure 5. MIC results of *C. tropicalis* (n=66) to fluconazole are shown in table 1. Mean ± SD for quantitative variable e.g. MIC are shown in table 1. The MIC results were categorized into three groups according to CLSI document M27-A2. The result shown were ≤8 Candida isolates were sensitive, 16-32 of Candida isolates were in SDD (susceptible dose dependent) category and ≥64 was counted as resistant.

After MIC and gene optimization as shown in fig 6, Real Time PCR was performed to find out the ERG11 gene expression in resistant isolates as compared to sensitive strains by using gene specific primers as shown in table and by considering Actin as housekeeping gene¹⁸. In the present study, fluconazole treatment induces an increase in ERG11 gene expression by two fold in resistant isolates than the susceptible *C. tropicalis* isolates as shown in figure 5. It suggests that fluconazole treatment over expressed the ERG11 gene mRNA in our resistant isolates. This increased expression of ERG11 gene leads to increased ergosterol production in the fungal cell membrane and decreased fluconazole susceptibility. So, in current study this overexpression played a significant role in mediating resistance in *C. tropicalis* isolates.

Relative gene expression of ERG11 gene showed 2.0 fold higher mRNA expression level in *C. tropicalis* resistant isolates than one fold increase in *C. tropicalis* susceptible isolates as shown in figure 5. Figure 6 shows gel electrophoresis for optimization of PCR amplification for gene ERG11.

Figure 1 Inoculation of microtiter plate



Table 1: Mean ± SD of sensitive and resistant *C. tropicalis*

MIC			
Sensitivity	Number	Mean	Std. Deviation
Sensitive	51	2.6471	1.49263
Resistant	7	194.2857	120.94863

Figure 2: Inoculum preparation for microdilution method




Figure 3: PCR thermal cycling conditions for CDNA synthesis




Figure 4: Actin PCR thermal cycling conditions



Figure 5: Antifungal susceptibility of *C.tropicalis* (n=66) to fluconazole




Figure 6: Relative Gene expression of ERG11 gene in sensitive and resistance *C. tropicalis*





Figure 7: Optimization of PCR amplification for gene ERG11



DISCUSSION

In our study, inhibition of azole antifungal to *C. tropicalis* were observed, the root cause of resistance of *C. tropicalis* to azole group could be rational application and limited side effects of these antifungals¹⁹. There is sufficient literature across the world that highlights the fact that high level of *Candida* species reluctance by usage of efflux pump or modification in the expression of ergosterol^{20, 21}. It has been brought in horizon, up regulation of ERG11 gene is entailed in the resistance phenotype of *Candida* species²². The current study demonstrated that relative gene expression of ERG11 in the two categories (sensitive and resistant *C. tropicalis*) were notably distinct (p value was < 0.001). Thus the up regulation of *C. tropicalis* ERG11 was correlated with responsiveness to fluconazole. A previous study of He et al displayed the up regulation of ERG11 and ABC2 perhaps responsible for the acquired itraconazole resistance in clinical isolates of *C. krusei*²³.

Similar to our study, the interpretation of Wang et al exhibited relative expression of ERG11 gene in drug resistance group was greater as comparable to the susceptible group²⁴. Fungal infections remain poorly studied and diagnosed as compared to other infectious diseases²⁵. Antifungal drug resistance in non albicans is at an alarming state²⁶ and is rising as a growing threat for public health. The various factors for resistance include the increased use of wide ranging antibiotics, increased use of medical devices etc. A study conducted Ostrosky et al in 2006 also supported current study results where 8% resistance to fluconazole was noted⁷. Similarly, a research conducted by Lockhart et al in 2012 declared 6.2% resistance to fluconazole in *C. tropicalis* which is in agreement with our current study²⁷. In contrast, across-sectional study conducted in Karachi showed no resistance to fluconazole in *C. tropicalis* by broth microdilution method²⁸. Another study carried out in Singapore also reported high susceptibility to fluconazole by disc diffusion method²⁹ the possible reason for the lack of resistance might be due to the absence of resistant genes in that *C. tropicalis* isolates.

An analysis of 52 clinical isolates of *C. Tropicalis* from China revealed that 31 azole resistant isolates had higher expression levels of ERG11 gene than 21 azole susceptible isolates¹⁴. Another study carried out by Choi et al narrated 3.4 fold higher ERG11 gene expression level in fluconazole non-susceptible isolates than fluconazole susceptible *C. tropicalis* isolates³⁰. Likewise, a study in China reported that missense mutations in ERG11 gene were the major mechanism of azole resistance in *C. tropicalis* isolates but increased expression of ERG11, CDR1, MDR1 and low expression level of CYTb also takes part in resistance. They reported 1.42 fold increased ERG11 gene expression level in fluconazole resistant isolates in opposition to 0.79 fold in fluconazole susceptible isolates³¹.

CONCLUSION

Resistance in non albicans species is an upsetting situation and it could be further increased in future. Further studies are required to tackle this increasing threat of emerging azole resistant *C. tropicalis* and to understand the different molecular mechanisms behind *C. tropicalis* drug resistance. There is a need to recognize

new drug targets and also to discover novel antifungal drugs against resistant organisms.

Practical implication: As limited data is available in Pakistan on *Candida* species antifungal susceptibility pattern, the molecular mechanisms involved in antifungal drug resistance. Our study will bring into limelight, the emerging *C. tropicalis* infections, their antifungal susceptibility patterns and the role of the molecular mechanism in antifungal resistance. This study will also help clinicians for the treatment of fungal infections accurately and facilitate in better management of patients.

Limitation: The confines of the current study concerns the sample size and mapping of other molecular techniques of ergosterol in rendering resistance to *C. tropicalis*. Thus the upcoming studies must entail large sample size and cloning and induction of non-synonymous mutation in ERG11 gene to indicate the modes of azole resistance.

Conflict of interest: Nil

REFERENCES

- Bongomin F, Gago S, Oladale RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. *J Fungi* 2017; 3:57.
- Formanek PE, Dilling DF. Advances in the diagnosis and management of invasive fungal disease. *Chest* 2019; 156:834-42.
- Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. *Trends Microbiol.* 2003 Jun 1; 11(6):272-9.
- Pinjon E, Jackson CJ, Kelly SL, Sanglard D, Moran G, Coleman DC, Sullivan DJ. Reduced azole susceptibility in genotype 3 *Candida dubliniensis* isolates associated with increased CDR1 and CDR2 expression. *Antimicrob. Agents Chemother.* 2005; Apr; 49(4):1312-8.
- Casalinuovo IA, Di Francesco P, Garaci E. Fluconazole resistance in *Candida albicans*: a review of mechanisms. *Eur Rev Med Pharmacol Sci* 2004; Mar 1; 8:69-78.
- Debnath S, Addya S. Structural basis for heterogeneous phenotype of ERG11 dependent Azole resistance in *C. albicans* clinical isolates. *Springerplus.* 2014; Dec; 3(1):1.
- Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. *Crit Care Med.* 2006; Mar 1; 34(3):857-63.
- White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of *Candida albicans*. *Antimicrob Agents Chemother.* Research Support, Non-U S Gov't Research Support, U S Gov't, P H S 2002; 46(6):1704-1713.
- White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of *Candida albicans*. *Antimicrob. Agents Chemother.* 2002; 46(6):1704-1713.
- Cowen LE, Steinbach WJ. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. *Eukaryot. Cell* 2008; May; 7(5):747-64.
- Zhang JY, Liu JH, Liu FD, Xia YH, Wang J, Liu X, Zhang ZQ, Zhu N, Ying Y, Huang XT. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression. *Mycoses* 2014; Oct; 57(10):584-91.
- Feng LJ, Wan Z, Wang XH, Li RY, Liu W. Relationship between antifungal resistance of fluconazole resistant *Candida albicans* and mutations in ERG11 gene. *Chin. Med* 2010; Mar 5; 123(05):544-8.
- Bizerra, F. C., Nakamura, C. V., De Poersch, C., Svidzinski, T. I. E., Quesada, R. M. B., Goldenberg, S., Krieger, M. A. & Yamada-Ogatta, S. F. 2008. Characteristics of biofilm formation by *Candida tropicalis* and antifungal resistance. *FEMS yeast research*, 8(3):442-450.
- Jiang, C., Dong, D., Yu, B., Cai, G., Wang, X., Ji, Y. & Peng, Y. 2012. Mechanisms of azole resistance in 52 clinical isolates of *Candida tropicalis* in China. *J. Antimicrob. Chemother.*, 68(4): 778-785.
- Ann Chai, L. Y., Denning, D. W. & Warn, P. 2010. *Candida tropicalis* in human disease. *Crit. Rev. Microbiol.*, 36(4): 282-298.
- Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Rolley N, Kelly DE, Kelly SL. Identification and characterization of four azole-resistant *erg3* mutants of *Candida albicans*. *Antimicrob. Agents Chemother.* 2010; Nov; 54(11):4527-33.
- Schwalbe R, Steele-Moore L, Goodwin AC. Antimicrobial susceptibility testing protocols. *Crc Press*; 2007; May 22.
- Vandeputte, P., Larcher, G., Bergès, T., Renier, G., Chabasse, D. & Bouchara, J.-P. 2005. Mechanisms of azole resistance in a clinical isolate of *Candida tropicalis*. *Antimicrob. Agents Chemother.* 49(11):4608-4615.

19. Kux L. Draft Guidance for Industry on Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations; availability. Fed Reg. 2012; 77: 9946.
20. Lamping E, Ranchod A, Nakamura K, Tyndall JD, Niimi K, Holmes AR, Niimi M, Cannon RD. *Abc1p* is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in *Candida krusei*. *Antimicrob. Agents Chemother* 2009; Feb;53(2):354-69.
21. Silva DB, Rodrigues LM, Almeida AA, Oliveira KM. Novel point mutations in the *ERG11* gene in clinical isolates of azole resistant *Candida* species. *Mem. Inst. Oswaldo Cruz*. 2016; Mar; 15;111:192-9.
22. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid substitutions in the *Candida albicans* *Erg11* protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. *Diagn. Microbiol. Infect.* 2010; Apr 1;66(4):373-84.
23. He X, Zhao M, Chen J, Wu R, Zhang J, Cui R, Jiang Y, Chen J, Cao X, Xing Y, Zhang Y. Overexpression of both *ERG11* and *ABC2* genes might be responsible for itraconazole resistance in clinical isolates of *Candida krusei*. *PLoS One*. 2015; Aug 26;10(8):e0136185.
24. Dan Wang1†, Na An2†, Yuwei Yang2, Xianggui Yang1, Yingzi Fan1 and JiafuFeng2. *Candida tropicalis* distribution and drug resistance is correlated with *ERG11* and *UPC2* expression. *Antimicrob Resist Infect Control* (2021) 10:54. 14.
25. Brown, G. D., Denning, D. W. & Levitz, S. M. 2012. Tackling human fungal infections.
26. Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N. & Castanheira, M. 2011. *Candida* bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. *Antimicrob. Agents Chemother.*, 55(2): 561-566.
27. Lockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R. & Park, B. J. 2012. Species identification and antifungal susceptibility testing of *Candida* bloodstream isolates from population-based surveillance studies in two US cities from 2008 to 2011. *J. Clin. Microbiol.*, 50(11): 3435-3442.
28. Farooqi, J., Jabeen, K., Saeed, N., Iqbal, N., Malik, B., Lockhart, S., Zafar, A., Brandt, M. & Hasan, R. 2013. Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility. *J. Med. Microbiol.*, 62(2): 259-268.
29. Oon, L. & Yeo, M. 2002. Fluconazole susceptibility of *Candida* species in Singapore by disc diffusion test. *Ann. Acad. Med. Singap.*, 31(4): 497-501.
30. Choi, M. J., Won, E. J., Shin, J. H., Kim, S. H., Lee, W.-G., Kim, M.-N., Lee, K., Shin, M. G., Suh, S. P. & Ryang, D. W. 2016. Resistance mechanisms and clinical features of fluconazole-non susceptible *Candida tropicalis* isolates compared with fluconazole-less-susceptible isolates. *Antimicrob. Agents Chemother.*, 60(6): 3653-3661.
31. Fan, X., Xiao, M., Zhang, D., Huang, J.-J., Wang, H., Hou, X., Zhang, L., Kong, F., Chen, S.-A. & Tong, Z.-H. 2019. Molecular mechanisms of azole resistance in *Candida tropicalis* isolates causing invasive candidiasis in China. *Clin. Microbiol. Infect.*, 25(7): 885-891.